PROSTATE CANCER 2008 2012 JOHNS HOPKINS HOSPITAL CANCER

PROSTATE CANCER 2008 - 2012 JOHNS HOPKINS HOSPITAL CANCER REGISTRY Prepared by Theresa San. Lorenzo-Caswell, CTR 09/01/2013

HEAD/NECK OF THE SKIN PROSTATE CANCER ANALYTIC vs. NON-ANALYTIC by YEAR 2008 -2012 N = 1800 ALL CASES = 6939 ANALYTIC vs. NON-ANALYTIC 1600 1400 NUMBER 1200 1000 800 600 400 200 0 ANALYTIC (6435) NON-ANALYTIC (503) 2008 1453 94 2009 1343 101 2010 1232 93 2011 1275 99 2012 1132 116

HEAD/NECK OF THE SKIN PROSTATE CANCER AGE AT DIAGNOSIS, ALL CASES 2008 -2012 N = 1800 ALL CASES = 6939 AGE AT DIAGNOSIS 3500 3000 NUMBER 2500 2000 1500 1000 500 0 MALE 30 - 39 15 40 - 49 519 50 - 59 2518 60 - 69 3047 70 - 79 754 80+ 86

PROSTATE CANCER 2008 -2012 ALL CASES = 6939 RACE/ETHNICITY 6000 5000 NUMBER 4000 3000 2000 1000 0 CAUCASIAN MALE 5595 AFRICAN AMERICAN 1070 HISPANIC OTHER 141 133

PROSTATE CANCER 2008 -2012 ALL CASES = 6939 STATE OF RESIDENCE AT DIAGNOSIS ALL OTHER STATES 15, 9% SC 2, 4% NY 2, 5% MD 42, 7% OUT OF COUNTRY 3, 0% DE 3, 0% FL 3, 4% NJ 3, 9% PA 11, 1% VA 12, 6%

PROSTATE CANCER 2008– 2012 ALL MARYLAND CASES = 2967 COUNTY OF RESIDENCE AT DIAGNOSIS ALL OTHER COUNTIES 17, 0% BALTIMORE CO. 15, 4% PRINCE GEORGES CO. 9, 2% BALTIMORE CITY 14, 1% HARFORD CO. 4, 1% FREDERICK CO. 4, 1% HOWARD CO. 8, 2% ANNE ARUNDEL CO. 12, 2% MONTGOMERY CO. 15, 7%

PROSTATE CANCER 2008 -2012 ANALYTIC CASES* n= 6237 AJCC STAGE AJCC IV 4, 5% AJCC III 19, 8% Not Applicable 0, 1% AJCC I 12, 9% AJCC II 62, 7% *Does not include class 0: Diagnosed at JHH only; all treatment elsewhere

PROSTATE CANCER 2008 -2012 ANALYTIC CASES* TREATMENT BY STAGE AJCC I (797) AJCC II (3912) AJCC III (1237) AJCC IV (282) Surgery 42. 1 73. 8 82. 7 25. 5 Radiation 14. 6 5. 8 0. 2 0. 7 Hormone 0. 8 0. 5 0. 4 34. 4 Active Surveillance 39. 8 8. 5 0 0. 7 Surgery & Radiation 0. 1 0. 3 7. 8 2. 1 Surgery & Hormone 0 0. 4 1. 5 6. 0 2. 6 9. 8 5. 0 17. 4 All Other Combinations 0 0. 5 2. 3 12. 1 Not Treated 0 0. 3 0. 1 100% 100% Radiation & Hormone *Does not include class 0 - Diagnosed at JHH only; all treatment elsewhere

PROSTATE 5 -YEAR OBSERVED SURVIVAL 2003 -2006 JHH vs. SEER vs. NCDB PERCENTAGE AJCC I 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% JHH (3*) SEER (239) NCDB (6057) YR 0 100, 0% YR 1 100, 0% 94, 1% 96, 9% YR 2 100, 0% 89, 5% 93, 6% YR 3 100, 0% 85, 3% 90, 4% YR 4 100, 0% 78, 5% 86, 8% YR 5 100, 0% 72, 9% 83, 0% © 2013 NCDB, Co. C *There was a change in AJCC Edition 6 and AJCC Edition 7, Starting with cases diagnosed in 2010. . This moved a ©SEER; SEER*STAT large number of previously Stage II to Stage I

PROSTATE 5 -YEAR OBSERVED SURVIVAL 2003 -2006 JHH vs. SEER vs. NCDB PERCENTAGE AJCC II 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% YR 0 JHH (3921) 100, 0% SEER (120, 684) 100, 0% NCDB (356, 242) 100, 0% © 2013 NCDB, Co. C ©SEER; SEER*STAT YR 1 99, 6% 98, 3% 98, 7% YR 2 99, 1% 96, 1% 97, 1% YR 3 98, 5% 93, 6% 95, 3% YR 4 97, 8% 90, 8% 93, 2% YR 5 97, 1% 87, 8% 90, 8%

PROSTATE 5 -YEAR OBSERVED SURVIVAL 2003 -2006 JHH vs. SEER vs. NCDB AJCC III PERCENTAGE 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% JHH (1095) SEER (9162) NCDB (36063) © 2013 NCDB, Co. C ©SEER; SEER*STAT YR 0 100, 0% YR 1 99, 7% 99, 0% YR 2 99, 4% 97, 5% YR 3 99, 3% 95, 5% 95, 6% YR 4 98, 6% 93, 5% 93, 4% YR 5 97, 6% 91, 0% 91, 1%

PROSTATE 5 -YEAR OBSERVED SURVIVAL 2003 -2006 JHH vs. SEER vs. NCDB AJCC IV 100% 90% 80% PERCENTAGE 70% 60% 50% 40% 30% 20% 10% 0% JHH (140) SEER (9058) NCDB (22600) © 2013 NCDB, Co. C ©SEER; SEER*STAT YR 0 100, 0% YR 1 90, 6% 77, 5% 77, 9% YR 2 81, 1% 60, 7% 61, 2% YR 3 76, 6% 50, 1% 50, 5% YR 4 71, 4% 42, 1% 43, 0% YR 5 69, 8% 37, 0% 37, 6%